Lung Cancer: State of the Art
CHEAP,Discount,Buy,Sale,Bestsellers,Good,For,REVIEW, Lung Cancer: State of the Art,Wholesale,Promotions,Shopping,Shipping,Lung Cancer: State of the Art,BestSelling,Off,Savings,Gifts,Cool,Hot,Top,Sellers,Overview,Specifications,Feature,on sale,Lung Cancer: State of the Art Lung Cancer: State of the Art
Lung Cancer: State of the Art Overview
Lung Cancer, State of the Art was awarded a Highly Commended accolade in the Oncology category at the British Medical Association (BMA) Medical Book Awards 2010.
Lung cancer is the most frequent cause of cancer deaths in the Western world today. Globally, it is estimated that 1.3 million patients die from lung cancer every year, and this figure is predicted to rise. Unfortunately, most patients present with regional or disseminated disease, and despite the treatment improvements made in the past decade the prognosis remains poor: in a best-case scenario the 5-year survival rate is approximately 15%. Thus, there is a critical need for more efficient therapy, particularly for patients with advanced disease.
This new book in Remedica’s State of the Art series contains up-to-date, comprehensive reviews by an international group of lung cancer experts on key topics in lung cancer, including the most recent advances in molecular biology, biomarkers, and molecular targeted therapies. All physicians who encounter patients with lung cancer will find that Lung Cancer: State of the Art provides a timely update on current and future treatment options. The book will enable readers to understand which treatment options hold the best hope for maximizing the quality of life, survival, and, ultimately, chance of cure in individual patients. Only by keeping abreast of the latest developments in this continually evolving field will clinicians be able to provide their patients with optimal care.
Contents: Epidemiology, etiology, and early detection; Pathology and molecular pathogenesis; Locally advanced non-small cell lung cancer; Adjuvant chemotherapy; Treatment of advanced non-small cell lung cancer; Perspectives on targeted therapies for non-small cell lung cancer; Management of small cell lung cancer; The clinical use of biomarkers in lung cancer.
Lung Cancer: State of the Art Specifications
Lung Cancer, State of the Art was awarded a Highly Commended accolade in the Oncology category at the British Medical Association (BMA) Medical Book Awards 2010.
Lung cancer is the most frequent cause of cancer deaths in the Western world today. Globally, it is estimated that 1.3 million patients die from lung cancer every year, and this figure is predicted to rise. Unfortunately, most patients present with regional or disseminated disease, and despite the treatment improvements made in the past decade the prognosis remains poor: in a best-case scenario the 5-year survival rate is approximately 15%. Thus, there is a critical need for more efficient therapy, particularly for patients with advanced disease.
This new book in Remedica’s State of the Art series contains up-to-date, comprehensive reviews by an international group of lung cancer experts on key topics in lung cancer, including the most recent advances in molecular biology, biomarkers, and molecular targeted therapies. All physicians who encounter patients with lung cancer will find that Lung Cancer: State of the Art provides a timely update on current and future treatment options. The book will enable readers to understand which treatment options hold the best hope for maximizing the quality of life, survival, and, ultimately, chance of cure in individual patients. Only by keeping abreast of the latest developments in this continually evolving field will clinicians be able to provide their patients with optimal care.
Contents: Epidemiology, etiology, and early detection; Pathology and molecular pathogenesis; Locally advanced non-small cell lung cancer; Adjuvant chemotherapy; Treatment of advanced non-small cell lung cancer; Perspectives on targeted therapies for non-small cell lung cancer; Management of small cell lung cancer; The clinical use of biomarkers in lung cancer.
